Patents by Inventor Teit E. Johansen

Teit E. Johansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic use of a growth factor, METRNL
    Patent number: 10034918
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: July 31, 2018
    Assignee: Hoba Therapeutics ApS
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Treatment of hyperalgesia, spontaneous pain, and phantom pain
    Patent number: 9861682
    Abstract: The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: January 9, 2018
    Assignee: HOBA THERAPEUTICS APS
    Inventors: Jesper Roland Jorgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • Therapeutic use of a growth factor, NsG33
    Patent number: 9845344
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: December 19, 2017
    Assignee: HOBA THERAPEUTICS APS
    Inventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Søren Brunak, Lars U. Wahlberg
  • Therapeutic Use of a Growth Factor, METRNL
    Publication number: 20170333526
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Application
    Filed: May 8, 2017
    Publication date: November 23, 2017
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Therapeutic use of a growth factor, METRNL
    Patent number: 9675669
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: June 13, 2017
    Assignee: HOBA THERAPEUTICS APS
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Treatment of Allodynia, Hyperalgsia, Spontaneous Pain, and Phantom Pain
    Publication number: 20170143794
    Abstract: The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.
    Type: Application
    Filed: September 27, 2016
    Publication date: May 25, 2017
    Applicant: NsGene A/S
    Inventors: Jesper Roland Jorgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • Treatment of allodynia
    Patent number: 9474786
    Abstract: The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: October 25, 2016
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jorgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
    Patent number: 9314502
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: April 19, 2016
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • THERAPEUTIC USE OF A GROWTH FACTOR, METRNL
    Publication number: 20160045564
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Application
    Filed: May 26, 2015
    Publication date: February 18, 2016
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Treatment of Allodynia, Hyperalgsia, Spontaneous Pain, and Phantom Pain
    Publication number: 20150231208
    Abstract: The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.
    Type: Application
    Filed: September 5, 2012
    Publication date: August 20, 2015
    Applicant: NSGENE A/S
    Inventors: Jesper Roland Jorgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • TREATMENT OF ALLODYNIA, HYPERALGESIA, SPONTANEOUS PAIN AND PHANTOM PAIN
    Publication number: 20150202262
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Application
    Filed: August 22, 2014
    Publication date: July 23, 2015
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • Therapeutic use of a growth factor, METRNL
    Patent number: 9068015
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: June 30, 2015
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
    Patent number: 8815810
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 26, 2014
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • TREATMENT OF ALLODYNIA, HYPERALGESIA, SPONTANEOUS PAIN AND PHANTOM PAIN
    Publication number: 20130303459
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 14, 2013
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • THERAPEUTIC USE OF A GROWTH FACTOR, METRNL
    Publication number: 20130267464
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Application
    Filed: December 14, 2012
    Publication date: October 10, 2013
    Applicant: NsGene A/S
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • NOVEL NEUROTROPHIC FACTORS
    Publication number: 20130109624
    Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
    Type: Application
    Filed: June 27, 2012
    Publication date: May 2, 2013
    Applicants: NSGENE A/S, BIOGEN IDEC MA INC.
    Inventors: Dinah W.Y. Sah, Teit E. Johansen, Anthony Rossomando
  • Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
    Patent number: 8404642
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: March 26, 2013
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • Therapeutic use of a growth factor, METRNL
    Patent number: 8334264
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: December 18, 2012
    Assignee: NsGenee A/S
    Inventors: Jesper Roland Jørgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • NOVEL NEUROTROPHIC FACTORS
    Publication number: 20120252726
    Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
    Type: Application
    Filed: April 11, 2011
    Publication date: October 4, 2012
    Applicant: NSGENE A/S
    Inventors: Teit E. Johansen, Nikolaj Blom, Claus Hansen
  • THERAPEUTIC USE OF A GROWTH FACTOR, NSG33
    Publication number: 20120184492
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.
    Type: Application
    Filed: December 15, 2011
    Publication date: July 19, 2012
    Applicant: NsGene A/S
    Inventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Soren Brunak, Lars U. Wahlberg